29 min listen
Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer
Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer
ratings:
Length:
9 minutes
Released:
Dec 9, 2022
Format:
Podcast episode
Description
2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.
At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.
Listen to the episode to hear Dr. Hurvitz explain:
overall survival and progression-free survival results
severe side effects of Enhertu
how the researchers managed any severe lung problems that developed in people receiving Enhertu
At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.
Listen to the episode to hear Dr. Hurvitz explain:
overall survival and progression-free survival results
severe side effects of Enhertu
how the researchers managed any severe lung problems that developed in people receiving Enhertu
Released:
Dec 9, 2022
Format:
Podcast episode
Titles in the series (100)
How Pets Help Us Heal: Michele Pich, psychologist and veterinary grief counselor, discusses therapy animals. by Breastcancer.org Podcast